Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Medical AI Inc.’s technology will provide fast, accurate diagnosis of cardiac problems, kidney failure, sepsis and anemia using hospital or home electrocardiogram devices.
Nabla Bio combines innovative artificial intelligence with proprietary wet-lab biology to design, refine and optimize next-generation therapeutic antibodies.
Precision medicine company Saphetor has built the world’s largest community and knowledge base for human genome variant identification, annotation, and interpretation. Through its open access platform and its clinical and application programming interface (API)-powered bespoke implementations, Saphetor helps researchers and clinicians accelerate understanding, diagnosis, and treatment of genetic conditions.
Exogene is using artificial intelligence to find rare, natural T cell receptors with a view to treating solid tumors and, ultimately, rejuvenating the immune system.
Scailyte’s artificial intelligence-powered platform, ScaiVision, identifies disease signatures that predict drug efficacy and describe drug mode of action to improve clinical outcomes for patients with complex diseases.
Nucleai’s innovative biomarker platform analyzes and interprets pathology data in both research and clinical settings to enhance diagnostics and improve patient treatment outcomes.
Designed to reshape drug discovery and drug repositioning, systems biology company DeepLife has created a data-driven technology platform that creates digital twins of human cells, to evaluate response to new drug candidates.
BIOS Health uses artificial intelligence (AI)-powered neural interfaces to understand the basis of chronic diseases and accelerate the development of treatments.
Compugen is driving the discovery and development of cancer immunotherapy drugs using its proprietary computational solutions, advanced new omics technologies and integration of computational discovery, wet-lab R&D experimentation and clinical trials.
Metabolic syndrome-derived medical conditions affect billions and costs trillions. MultiOmic Health will combine artificial intelligence and wet lab experimentation with the proprietary multi-omic data it is accumulating to create new precision medicines for these conditions.
Oncology-focused partnerships drove record-level licensing deals in 2021 as companies looked to gain access to novel therapeutic targets and platforms.
POINT Biopharma is a late-stage precision oncology company, focused on developing and bringing to market next generation radioligand therapies. These therapies are like microscopic, cancer-seeking missiles, that precisely deliver radiation to tumors, against a range of cancers.
Priothera’s small molecule mocravimod is transforming the prospects of patients with hematological malignancies receiving hematopoietic stem cell transplants.
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
The Danish biotech company MonTa Biosciences has developed a novel immunotherapeutic nanoparticle that is currently in a phase 1 clinical trial in patients with solid tumors.
Following its success in the veterinary market, QBiotics is now developing tigilanol tiglate for use against solid tumors in humans via intratumoral injection.